Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dermatology/Dermatitis

Dermatitis

117

Pipeline Programs↗

208

Active Trials↗

161

Companies Involved↗

Dermatitis is a highly competitive landscape with 117 programs across 161 companies. 30 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

87/100

Mech. Concentration

21/100

Completion Rate

84/100

Attrition Rate

12/100

Pipeline

Programs by Phase

Preclinical41

Bilastine

Menarini International Operations Luxembourg SA

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Clindamycin

Pfizer

Diclofenac Sodium

Novartis

Strataxrt

Mayo Clinic

Phase 111

Ssgj-716

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Regn20423

Regeneron

Hrs-8797

Chengdu Suncadia Medicine Co., Ltd.

PF-07832837

Pfizer

Byn-001

Bionyra Pharma

Phase 235

JAK Inhibitor

Fred Hutchinson Cancer Center

Afimkibart

Roche

FB825

Oneness Biotech Co., Ltd.

IMG-007

Inmagene LLC

KT-621

Kymera Therapeutics, Inc.

Phase 330

Tralokinumab

LEO Pharma

SHR-1819

Guangdong Hengrui Pharmaceutical Co., Ltd

VC005

Jiangsu vcare pharmaceutical technology co., LTD

Rezpegaldesleukin

Nektar Therapeutics

Topical Corticosteroid (TCS)

Cairo University

Approved

No programs

Analysis

Modality Breakdown

86%

Small molecule

80 of 93 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 93 classified programs, each share of the total. Modality classified for 89% of 117 pipeline programs.

Analysis

Trial Status

984

clinical trials

Completed611 · 62%

Recruiting111 · 11%

Terminated78 · 8%

Unknown status48 · 5%

Not yet recruiting47 · 5%

Active, not recruiting44 · 4%

Other45 · 5%

Clinical Trials

Trial Activity

984 trials

Effects of Glycyrrhetinic Acid on Human Skin in an Acute Irritant Contact Dermatitis Model

Recruiting·UUniversity of Split, School of Medicine·Preclinical·NCT07286487·30 enrolled

A Phase 1 Study With a Single Ascending Dose-escalation in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of QX-4533 and a Randomized, Double-Blind, Placebo-Controlled, Parallel Group to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of QX-4533 in Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting·QQuantX Biosciences, Inc.·Phase 1·NCT07800104·84 enrolled

Evaluation of a Non-Invasive Device for Early Detection of Flares in Adults and Adolescents With Atopic Dermatitis

Recruiting·CCastle Biosciences Incorporated·N/A·NCT07645820·450 enrolled

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting·NNektar Therapeutics·Phase 3·NCT07690371·510 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis

Recruiting· UCB logo

UCB·Phase 2·NCT07277660·160 enrolled

A Phase 1a/1b, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 in Healthy Volunteers and Subjects With Moderate to Severe Atopic Dermatitis.

Recruiting·AArcutis Biotherapeutics, Inc.·Phase 1·NCT07453602·125 enrolled

AIMSI Trial : Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults

Recruiting·UUniversity Hospital, Caen·Preclinical·NCT07358000·86 enrolled

A Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients

Recruiting·HHK inno.N Corporation·Phase 2·NCT07073677·162 enrolled

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

Recruiting·UUniversity of California, San Francisco·Approved·NCT07487831·50 enrolled

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 3·NCT07309055·201 enrolled

Changes in Fungal Mycobiome, Bacterial Microbiome, and Abundance of Staphylococcus Species After Lebrikizumab Treatment - a Prospective Multicenter Observational Cohort Study

Recruiting·UUniversity Hospital Bispebjerg and Frederiksberg·N/A·NCT07807228·60 enrolled

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis

Recruiting·NNektar Therapeutics·Phase 3·NCT07711418·510 enrolled

Outcomes of a Digital Mindfulness Meditation App-Based Intervention in Adolescents With Moderate to Severe Atopic Dermatitis (MIND-AD)

Recruiting·WWeill Medical College of Cornell University·Preclinical·NCT07746427·40 enrolled

A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777

Recruiting·AApogee Therapeutics, Inc.·Phase 2·NCT07003425·350 enrolled

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Recruiting· Roche logo

Roche·Phase 2·NCT07223697·120 enrolled

Page 1 of 66

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)